Why Supplement Companies Hide Dosages: What to Know

Many supplement labels hide per-ingredient dosages using a legally permitted loophole called a “proprietary blend” — so treat any blend without disclosed milligram amounts as unverified, and run a quick arithmetic check before you buy.

Under the Dietary Supplement Health and Education Act (DSHEA, 21 U.S.C. § 321(ff)), supplements face far lighter labeling requirements than drugs. A company can list ten active ingredients under one blend total and never tell you how much of each is inside. That is not an accident or an oversight. It is a deliberate combination of regulatory gaps, cost-saving tactics, and marketing strategy.

The short version:

• Any product listing a “proprietary blend” without per-ingredient milligram amounts is unverified by definition.
• Prefer products that disclose every ingredient’s exact dose and provide third-party Certificates of Analysis (COAs).
• Independent seals from NSF International, USP, or ConsumerLab add a layer of verification, but they do not guarantee clinical doses unless the testing specifically checks label-claim accuracy.
• The FDA cannot require pre-market approval for most supplements and can only act after harm is documented.
• The arithmetic test: add up the minimum effective doses for each active in a blend. If that sum exceeds the blend’s total weight, at least one ingredient is underdosed.

Table of Contents

• How does U.S. supplement labeling actually work?
• Why do companies hide dosages in the first place?
• What do studies and FDA actions actually show?
• Why does the exact dose matter so much?
• How can you spot a risky supplement when shopping?
• What can regulators actually do right now?
• What should you do if a supplement harms you?
• What is the bottom line for your buying decisions?
• Key Takeaways
• The case for radical transparency in supplements
• Transparent supplements without the guesswork
• Authoritative sources and further reading

How does U.S. supplement labeling actually work?

The legal foundation here is DSHEA, passed in 1994, which defined dietary supplements as a separate category from drugs and foods under 21 U.S.C. § 321(ff). That single legislative decision shifted the burden of proof: instead of a company proving a supplement is safe before selling it, the FDA must prove it is unsafe before pulling it. No pre-market approval required.

Labeling falls under 21 CFR 101.36, which governs the Supplement Facts panel. The rule requires that a proprietary blend list all its ingredients in descending order by weight and show the blend’s total weight. What it does not require is the milligram amount for each individual component. A company can put 1,000 mg of a blend on the label, list eight ingredients underneath it, and legally tell you nothing more.

The “descending order” requirement sounds reassuring, but it has a real flaw. The FDA’s own labeling guide acknowledges that adjacent ingredients in a list can differ by as little as a fraction of a milligram. The first ingredient on the list could be 500 mg, or it could be 126 mg with the second ingredient at 125 mg. You cannot tell from the label. That gap is wide enough to drive a truck through.

Regulatory gap in plain terms: 21 CFR 101.36 requires a blend total and descending-order listing, but it does not require per-ingredient disclosure. A label that shows “Proprietary Blend 800 mg” with six actives listed beneath it is fully compliant with federal law, even if five of those actives are present at trace amounts.

Third-party seals from NSF International, USP, and ConsumerLab do add genuine value. They verify that a product contains what the label claims and is free from contaminants. But unless the testing protocol specifically checks each ingredient against a clinical dose threshold, a seal confirms identity and purity, not effectiveness. A product can carry an NSF seal and still contain a fairy-dusted dose of its star ingredient.

For a deeper look at how these regulatory gaps affect consumers, the structural problem runs deeper than any single bad actor.

Why do companies hide dosages in the first place?

The honest answer is that hiding dosages is profitable. Three distinct motives drive it, and they often overlap.

Trade secrets versus practical reality. Companies frequently claim proprietary blends protect their formulas from competitors. The argument has some surface logic, but it does not hold up technically. Any laboratory with basic chromatography equipment can reverse-engineer a supplement formula relatively quickly. The Council for Responsible Nutrition (CRN) has acknowledged in its own commentary that proprietary blends are often used to conceal low doses rather than protect genuinely novel formulas. If the formula were truly novel, a patent would offer far stronger protection than a blend label.

Cost savings through fairy dusting. This is the most common motive. Expensive ingredients like ashwagandha extract, lion’s mane, or L-citrulline cost significantly more per gram than fillers like maltodextrin or taurine. A company can include a clinically meaningful name on its label while actually delivering a fraction of the therapeutic dose. The ingredient appears, the marketing copy can reference it, and the cost stays low. That practice has a name in the industry: fairy dusting.

Science-washing. Marketing teams cite peer-reviewed clinical trials to support product claims, but those trials were conducted on single ingredients at specific doses. A finished product that contains that ingredient at a sub-clinical level cannot legitimately claim the same outcomes. The CRN’s analysis and independent nutrition researchers have both flagged this as a widespread tactic. The study is real; the dose in the bottle is not.

Formulation levers that inflate the appearance of a formula:

• Serving-size inflation: spreading a small amount of actives across a large serving to make the total weight look substantial.
• Nested blends: a blend inside a blend, which adds another layer of opacity.
• Cheap fillers listed early in a blend to push expensive actives further down the weight ranking.
• Undisclosed caffeine sources (guarana, green tea extract) that mask stimulant content.

Pro Tip: Run the arithmetic test before buying. Add up the minimum effective doses for each active ingredient in a blend. If that sum is larger than the blend’s total weight, at least one ingredient is mathematically underdosed. A pre-workout listing creatine, beta-alanine, L-citrulline, and caffeine in a modestly sized blend cannot contain clinical doses of all four — those four ingredients alone require significantly more than the total blend weight for minimum effective levels.

Understanding why filler ingredients appear in so many formulas helps decode what you are actually reading on a label.

What do studies and FDA actions actually show?

The evidence that hidden dosages cause real harm is not theoretical. Peer-reviewed research, government investigations, and FDA enforcement actions document a pattern of mislabeling, contamination, and outright fraud across the supplement industry.

A 2015 PMC analysis titled “Too Little, Too Late: Ineffective Regulation of Dietary Supplements” concluded that DSHEA’s post-market enforcement model leaves consumers systematically exposed because the FDA cannot act until harm is documented. The Government Accountability Office has separately documented that the FDA received thousands of adverse event reports linked to supplements, yet the agency’s enforcement capacity remains limited relative to the size of the market.

Harvard Health Publishing has noted that supplements have been found to contain prescription drugs, heavy metals, and undisclosed stimulants, none of which appear on the label. These are not edge cases from obscure brands.

The core problem, stated plainly: The FDA does not review or approve supplement products before they reach store shelves. A company can formulate, label, and sell a product without ever submitting it to any government agency for review. By the time an enforcement action occurs, consumers have already been exposed.

The FDA does issue warning letters and conduct recalls, but these actions are reactive. A product must already be on the market, and harm must already be documented or a serious labeling violation identified, before the agency can move. For a detailed look at how contaminated supplements reach shelves, the supply-chain vulnerabilities are significant.

Why does the exact dose matter so much?

Dose is not a technicality. Every clinical trial that established a supplement’s efficacy did so at a specific dose, and that dose was chosen because lower amounts did not produce the same effect. Below a certain threshold, many ingredients produce no measurable benefit at all.

Research published on PubMed establishes minimum effective doses for common supplement ingredients that are routinely found in proprietary blends:

• Creatine monohydrate: 3–5 g per day for strength and performance benefits.
• Beta-alanine: approximately 3.2 g per day to raise muscle carnosine levels meaningfully.
• L-citrulline: approximately 6 g per dose for measurable nitric oxide and performance effects.
• Caffeine: 150–300 mg for cognitive and physical performance outcomes.
• Ashwagandha: 300–600 mg of a standardized extract for stress and recovery effects.
• Betaine: approximately 2.5 g per day for power output benefits.

Now apply the arithmetic test to a real-world scenario. A pre-workout product lists a “Performance Matrix” blend at 4,500 mg. Inside that blend: creatine, beta-alanine, L-citrulline, caffeine, betaine, and ashwagandha. The minimum effective doses for those six ingredients alone total roughly 15,450 mg. The blend contains 4,500 mg. The math is not close.

Statistic callout: A blend listing six common performance actives at their minimum effective doses would require a total weight far exceeding typical blend sizes. A blend of moderate total weight containing all six cannot deliver clinical doses of any single one of them.

This is fairy dusting in arithmetic form. The ingredient names appear on the label. The clinical doses do not exist in the bottle. A consumer reading only the ingredient list would have no way to know this without doing the math themselves, which is exactly why supplement dosage labeling reform matters.

How can you spot a risky supplement when shopping?

The checklist below is designed as a quick screen you can run in under two minutes, whether you are standing in a store or browsing online.

Step-by-step shopping flow:

1. Check for proprietary blends first. If the Supplement Facts panel shows a blend total without individual milligram amounts for each ingredient, flag it immediately. That is the single biggest red flag in supplement dosage labeling.
2. Scan for disclosed milligram amounts. Every active ingredient should have its own milligram amount listed. If you see “Proprietary Blend 1,200 mg” with six ingredients beneath it and no individual amounts, move on.
3. Look for third-party seals. NSF International, USP, ConsumerLab, and Informed Sport all conduct independent testing. A seal does not guarantee clinical dosing, but it does confirm the product contains what it claims and is free from banned substances or contaminants.
4. Request or locate the COA. A Certificate of Analysis is a lab report showing what was actually found in a tested batch. Credible brands publish these on their website or provide them on request. If a company cannot or will not produce a COA, that tells you something.
5. Check the company’s transparency resources. Does the brand publish its sourcing, testing protocols, and formulation rationale? Brands that invest in evaluating wellness product transparency tend to stand behind their labels.

Red flags to avoid:

• Proprietary blends with many actives and a small total weight.
• Nested blends (a blend inside a blend) with no individual disclosures.
• Undisclosed caffeine sources such as guarana or green tea extract listed without milligram amounts.
• Claims citing clinical studies without disclosing whether the product matches the studied dose.
• No COA available and no response from customer support when asked.
• Unrealistic health claims that would require FDA drug approval if made by a pharmaceutical.

Positive signals to prefer:

• Full label disclosure: every ingredient has its own milligram amount.
• Published batch COAs accessible on the product page or by request.
• Third-party verification from NSF, USP, or ConsumerLab.
• Customer support that can answer specific questions about doses and testing.
• A company that names its testing lab and publishes results by lot number.

Pro Tip: When you find a COA, check three things: the lot number matches the product you are buying, the tested amounts match the label claims within a reasonable margin (typically ±10%), and the testing lab is accredited (look for ISO 17025 accreditation). A COA from an unaccredited lab is better than nothing, but it is not the same as independent verification.

What can regulators actually do right now?

The FDA’s authority over supplements is genuinely constrained by DSHEA’s structure. Under the current framework, the agency does not review or approve supplements before they go to market. To pull a product, the FDA must demonstrate that it is unsafe, adulterated, or misbranded — after the fact. That is a high bar that requires documented harm and significant agency resources.

The FDA can and does issue warning letters, conduct inspections, and initiate recalls. But the supplement market is large, the agency’s resources are finite, and the post-market model means consumers absorb the risk during the period between a product’s launch and any enforcement action.

The structural problem: DSHEA placed the burden of proof on the FDA to demonstrate harm rather than on manufacturers to demonstrate safety. That single design choice in 1994 created the regulatory environment that makes hidden dosages and mislabeling possible at scale today.

The most significant proposed reform currently in Congress is the Dietary Supplement Listing Act of 2026, introduced by Sen. Durbin. The bill would require supplement companies to register their products with the FDA in a public electronic registry, including full ingredient lists and labels. That is a meaningful step toward accountability.

The catch: proprietary blend compositions would be shared with the FDA but kept confidential from the public. Consumers would know a product is registered, but they still would not see per-ingredient doses. Reporting on the bill has noted that industry groups pushed hard for that confidentiality provision.

Key regulatory milestones to watch:

• 1994: DSHEA enacted; supplements defined separately from drugs; pre-market approval not required.
• 2007: FDA issued Current Good Manufacturing Practice (cGMP) rules for supplements, requiring quality controls but not pre-market efficacy review.
• 2026: Dietary Supplement Listing Act introduced; public registry proposed with confidential blend details.
• Near-term: Watch for any amendment requiring COA availability or independent verification as a condition of registry listing.

The supplement regulation landscape continues to evolve, but meaningful public disclosure of per-ingredient doses is not yet on the legislative table.

What should you do if a supplement harms you?

If you experience an adverse reaction or suspect a product is mislabeled, act in a specific order. Documentation matters for both your health and any formal complaint.

1. Stop using the product immediately. Do not discard it.
2. Preserve the bottle. Keep the original container with its label, lot number, and expiration date intact. Photograph the Supplement Facts panel, the lot number, and any visible damage or unusual appearance.
3. Note your purchase details. Save the receipt, order confirmation, or bank statement showing where and when you bought the product.
4. Seek medical attention if needed. If symptoms are serious, go to an emergency room or urgent care. Tell the provider exactly what you took, including the product name, dose, and timing. Keep all medical records and bills.
5. Report to FDA MedWatch. File a report at FDA MedWatch (fda.gov/safety/medwatch). You can report online, by phone, or by mail. Include the lot number, product name, manufacturer, and a description of the adverse event.
6. Report to your state health department. Many states have their own consumer protection and food safety divisions that track supplement complaints independently of the FDA.
7. Contact the retailer or marketplace. Request a refund and flag the product. Major retailers and online marketplaces have their own reporting mechanisms; a complaint from a consumer can trigger an internal review.
8. Contact the third-party certifier if applicable. If the product carries an NSF, USP, or ConsumerLab seal and you believe the product does not match its label, report directly to that certifier. They have the authority to revoke certification and conduct follow-up testing.

Keep copies of everything: photos, receipts, medical records, and any correspondence with the company or retailer. If you pursue a chargeback through your credit card, that documentation is what makes the dispute winnable.

What is the bottom line for your buying decisions?

Assume any proprietary blend is unverified until proven otherwise. That is not cynicism; it is the logical consequence of a labeling system that legally permits companies to withhold per-ingredient doses.

Three rules cover most situations:

• Avoid blends unless every dose is disclosed. If the label does not show milligram amounts for each active, the product cannot be verified against clinical thresholds.
• Verify COAs before buying. A published, lot-specific Certificate of Analysis from an accredited lab is the strongest signal that a product contains what it claims.
• Favor third-party seals, but understand their limits. NSF, USP, and ConsumerLab verify identity and purity. They do not automatically confirm that doses meet clinical thresholds unless label-claim accuracy testing is part of the protocol.

Transparency is the single best proxy for likely effectiveness. A company willing to disclose every milligram and publish its lab results has far less to hide than one that does not.

The arithmetic test is your fastest screen. If a blend’s total weight cannot mathematically accommodate clinical doses of all its listed actives, at least one is underdosed. That calculation takes about 60 seconds and tells you more than any marketing claim on the front of the bottle.

Key Takeaways

Supplement companies hide per-ingredient dosages primarily because U.S. law (DSHEA and 21 CFR 101.36) permits proprietary blends that disclose only a total weight, creating a legal cover for cost-cutting and marketing tactics that leave consumers unable to verify clinical doses.

The case for radical transparency in supplements

The supplement industry’s opacity is not a side effect of complexity. It is a business model. When a company can list an ingredient at 5 mg, cite a clinical trial that used 500 mg, and face no legal obligation to disclose the gap, the incentive to be honest is purely reputational. For most brands, that reputational pressure has not been enough.

What is changing is the consumer side of that equation. Buyers who understand the arithmetic test, who know to ask for COAs, and who recognize science-washing when they see it are a different kind of customer than the one the proprietary-blend model was designed for. The shift toward full-label disclosure and published batch testing is not altruism from manufacturers; it is a response to a segment of the market that has stopped accepting opacity as normal.

The Dietary Supplement Listing Act of 2026 is a step, but a limited one. A public registry that still withholds blend compositions from consumers does not solve the core problem. The real reform would require per-ingredient disclosure as a condition of sale, not just registration. Until that happens, the burden stays on the consumer, and the arithmetic test stays the most reliable tool available.

Mycelia Link’s position is straightforward: full disclosure is the floor, not a differentiator. Every product should list every milligram. Every batch should have a COA. Anything less is asking consumers to trust marketing copy over verifiable evidence, and that is not a trade worth making.

Transparent supplements without the guesswork

Most supplement brands ask you to trust the label. Mycelia Link asks you to check it.

Mycelia Link’s functional mushroom supplements and research peptide products list every ingredient’s milligram amount on the label and back each batch with published COAs from accredited labs. No proprietary blends. No fairy-dusted actives. No marketing copy standing in for real data. The price reflects what is actually in the formula, not what the packaging implies.

If you want to see what full label transparency looks like in practice, the supplement transparency guide walks through exactly what to look for and how Mycelia Link’s products are documented. Browse the mushroom supplement and peptide categories, pull up a COA, and compare it against the label. That is the standard every supplement should meet.

Authoritative sources and further reading

• FDA: Dietary Supplement Labeling Guide, Chapter IV — Official FDA guidance on 21 CFR 101.36, proprietary blend rules, and descending-order requirements.
• FDA: Questions and Answers on Dietary Supplements — Plain-language FDA overview of what the agency can and cannot regulate.
• PMC: “Too Little, Too Late: Ineffective Regulation of Dietary Supplements” — Peer-reviewed analysis of DSHEA’s structural enforcement limits.
• PMC: Dietary supplement labeling and proprietary blends — Academic review of 21 CFR 101.36 and the legal basis for hidden dosages.
• PubMed: Minimum effective doses for common supplement ingredients — Aggregated clinical research establishing dose thresholds for creatine, beta-alanine, L-citrulline, and other common actives.
• Harvard Health Publishing: What’s in your supplements? — Consumer-facing review of contamination and mislabeling findings.
• GAO: Dietary Supplement Report — Government Accountability Office documentation of adverse event reports and FDA enforcement capacity.
• Dietary Supplement Listing Act of 2026 (Congress.gov) — Full legislative text of the proposed product registry bill.
• NutraIngredients: Sen. Durbin introduces Dietary Supplement Listing Act of 2026 — Industry reporting on the bill’s provisions and confidentiality protections.
• CRN: Proprietary Blends Analysis — Industry self-analysis acknowledging that blends are often used to conceal low doses rather than protect IP.
• Mycelia Link: Supplement Transparency Best Practices — Brand-aligned consumer guide to reading labels, verifying COAs, and identifying red flags.

This article is general consumer information, not medical or legal advice. Verify current regulations and product details with the FDA or a qualified health professional before making decisions about your specific situation.

Recommended

• Why Filler Ingredients Are Used in Supplements
• Why Discount Supplements Risk Quality: What to Know
• Supplement Transparency Best Practices: 2026 Consumer Guide
• How the Supplement Industry Lacks Regulation in 2026